{"product_id":"lange-clinical-neurology-11th-edition-9781260458350","title":"Lange Clinical Neurology 11th Edition","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eThe clearest, most concise coverage of one of the most complex topics in medicineâupdated with the latest advances in the field\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDoody's Core Titles for 2023!\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eClinical Neurology, Eleventh Edition, provides a comprehensive overview of basic and clinical neurology in a concise, digestible format. It links clinical neuroscience to current approaches for accurately diagnosing and effectively treating neurologic disorders. Covering all the advances in molecular biology and genetics, this popular guide emphasizes history-taking and neurologic examination as the cornerstones of diagnosis. All information is thoroughly up-to-date and presented as a practice-oriented approach to neurology based on the patient's presenting symptoms or signs.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003eFeatures:\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e350+ tables and figures\u003c\/li\u003e\n\u003cli\u003eChapter outlines providing overview of each topic\u003c\/li\u003e\n\u003cli\u003eTreatment protocols reflecting the most recent advances in the field\u003c\/li\u003e\n\u003cli\u003eStep-by-step review of the ne\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eChapter 1. NeurologicHistory \u0026amp; Examination\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eNeurologic examination ofsphincter function\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 2. InvestigativeStudies\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNeuromuscular imaging studies\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eUpdate on ultrasonography forneuromuscular diagnosis\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 3. Coma\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eIntroduction\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eRole of prefrontal cortex in consciousness\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCauses of coma\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eSpontaneous intracranialhypotension as a cause of coma\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePersistent vegetative state\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eNew imaging insights intopersistent vegetative \u0026amp; minimally conscious states\u003c\/p\u003e\n\u003cp\u003eTreatment of traumatic vegetative \u0026amp;minimally conscious states with amantadine\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 4. ConfusionalStates\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eDrugs\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eSerotonin syndrome\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eElectrolyte disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eAntidepressant-inducedhyponatremia\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eEndocrine \u0026amp; metabolic disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eMechanisms of impairedhypoglycemia sensing in treated diabetes\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNutritional disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eFurosemide-induced thiaminedeficiency\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOrgan system failure\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eICU delirium\u003c\/p\u003e\n\u003cp\u003ePostoperative cognitivedysfunction\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMeningitis, encephalitis \u0026amp; sepsis\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eMechanism of \u003ci\u003eN. meningitidis\u003c\/i\u003e vascular spread\u003c\/p\u003e\n\u003cp\u003eDysregulated host inflammatoryresponse in tuberculous meningitis\u003c\/p\u003e\n\u003cp\u003eCSF findings in HIV-infectedpatients with tuberculous meningitis\u003c\/p\u003e\n\u003cp\u003eTick-borne encephalitis \u0026amp; (re-emergent)yellow fever\u003c\/p\u003e\n\u003cp\u003eNipah virus encephalitis\u003c\/p\u003e\n\u003cp\u003eUpdated diagnostic testing forviral encephalitis\u003c\/p\u003e\n\u003cp\u003eNew recommendation on empiricaltreatment of toxoplasmosis in AIDS\u003c\/p\u003e\n\u003cp\u003eFexinidazole for treatment of Africantrypanosomiasis \u003c\/p\u003e\n\u003cp\u003eMechanism of meningeal invasion inleukemia\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 5. Dementia\u0026amp; Amnestic Disorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eIntroduction\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eSomatic neuronal mutations in aging and neurodegeneration\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eDifferential diagnosis\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eBiomarker-based diagnostic algorithms for dementia syndromes\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNeurodegenerativeproteinopathies\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eTau folding in Alzheimer vs. Pickdisease\u003c\/p\u003e\n\u003cp\u003eTau-disrupted nucleocytoplasmictransport in Alzheimer disease pathogenesis\u003c\/p\u003e\n\u003cp\u003eContrasting mechanisms ofaggregate toxicity in neurodegeneration\u003c\/p\u003e\n\u003cp\u003eHerpes simplex virus infection andAlzheimer disease\u003c\/p\u003e\n\u003cp\u003eInflammation in Alzheimer diseasepathogenesis\u003c\/p\u003e\n\u003cp\u003eMeningeal lymphatics (glymphatics)in Alzheimer disease pathogenesis\u003c\/p\u003e\n\u003cp\u003eBlood pressure and risk of Alzheimerdisease\u003c\/p\u003e\n\u003cp\u003eRelation between epilepsy anddementia\u003c\/p\u003e\n\u003cp\u003eExercise training in dementia\u003c\/p\u003e\n\u003cp\u003eSex differences in Alzheimerdisease\u003c\/p\u003e\n\u003cp\u003eSpatial navigation deficits asearly signs of Alzheimer disease\u003c\/p\u003e\n\u003cp\u003eSubjective cognitive decline in relationto Alzheimer disease\u003c\/p\u003e\n\u003cp\u003eUpdate on biomarkers for Alzheimerdisease\u003c\/p\u003e\n\u003cp\u003eConcomitant neurodegenerativeproteinopathies\u003c\/p\u003e\n\u003cp\u003eUpdate on clinical trials oftreatments for Alzheimer disease (eg, solanezumab, verubecestat)\u003c\/p\u003e\n\u003cp\u003eClinical and pathologicalcorrelates of primary progressive aphasia variants\u003c\/p\u003e\n\u003cp\u003eNew consensus guidelines fordiagnosis \u0026amp; treatment of dementia with Lewy bodies\u003c\/p\u003e\n\u003cp\u003eSkin prions in Creutzfeldt-Jakobdisease infectivity and diagnosis\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOther cerebral disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eShunting response to gait vs. dementia in normal pressurehydrocephalus\u003c\/p\u003e\n\u003cp\u003eNormal pressure hydrocephalus vs.neurodegenerative ventriculomegaly\u003c\/p\u003e\n\u003cp\u003eMild traumatic brain injury \u0026amp; dementia\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSystemic disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eSubclinical hyperthyroidism \u0026amp;dementia\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePseudodementia\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eFeatures of memory impairment in depression\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAmnestic syndromes\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eUpdate on antibody-mediatedencephalitis antigens \u0026amp; treatment\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 6. Headache\u0026amp; Facial Pain\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMigraine\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eTriptans, SSRIs \u0026amp; serotoninsyndrome\u003c\/p\u003e\n\u003cp\u003eCGRP receptor-blocking monoclonalantibodies (eg, erenumab, fremanezumab)\u003c\/p\u003e\n\u003cp\u003eProchlorperazine plusdiphenhydramine vs. hydromorphone for IV migraine therapy\u003c\/p\u003e\n\u003cp\u003eVagus nerve stimulation as acute therapyfor migraine\u003c\/p\u003e\n\u003cp\u003eReconsideration of medicationoveruse headache\u003c\/p\u003e\n\u003cp\u003eUpdate on sustained release drugs\u003c\/p\u003e\n\u003cp\u003eSafety of migraine drugs in pregnancyand breast-feeding\u003c\/p\u003e\n\u003cp\u003eCluster headache\u003c\/p\u003e\n\u003cp\u003e       CGRPreceptor-blocking monoclonal antibodies \u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eGiant cell arteritis\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eTocilizumab for treatment ofgiant-cell arteritis\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eIntracranial mass\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eMolecular classification of braintumors\u003c\/p\u003e\n\u003cp\u003eSubventricular zone origin ofglioblastoma multiforme\u003c\/p\u003e\n\u003cp\u003eNivolumab plus ipilimumab formelanoma brain metastases\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 7. Neuro-OphthalmicDisorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eUpdate on imaging of optic nervedisorders (optical coherence tomography)\u003c\/p\u003e\n\u003cp\u003eNonarteritic anterior ischemic optic neuropathy inobstructive sleep apnea\u003c\/p\u003e\n\u003cp\u003eErectile dysfunction drugs \u0026amp; nonarteritic anterior ischemicoptic neuropathy\u003c\/p\u003e\n\u003cp\u003eUpdated consensus management ofpseudotumor cerebri\u003c\/p\u003e\n\u003cp\u003eUpdate on imaging of giant cellarteritis (ultrasound, MRI, PET)\u003c\/p\u003e\n\u003cp\u003eCharles Bonnet syndrome incortical blindness\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 8. Disordersof Equilibrium\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNew Figure:\u003c\/i\u003e Sites of involvement in peripheral vestibular disorders\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePeripheral vestibular disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eSelf-treatment of benign paroxysmal positional vertigo\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCerebellar \u0026amp; central vestibulardisorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eAutoimmune septin-5 cerebellarataxia\u003c\/p\u003e\n\u003cp\u003eCerebellar histiocytosis\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSensory ataxias\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eNonataxic symptoms in FriedreichAtaxia\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 9. MotorDisorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSpinal cord disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eIbudilast for treatment of progressivemultiple sclerosis\u003c\/p\u003e\n\u003cp\u003eSimvastatin for cognitivedysfunction in secondary progressivemultiple sclerosis\u003c\/p\u003e\n\u003cp\u003eClinical differentiation oftransverse myelitis etiologies\u003c\/p\u003e\n\u003cp\u003eCircumferential resectioncord-compressing tumors (vs. decompressive laminectomy)\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAnterior horn cell disorders\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eKinesin family member 5A (KIF5A) mutationsassociated with ALS\u003c\/p\u003e\n\u003cp\u003eEdaravone for treatment of ALS\u003c\/p\u003e\n\u003cp\u003eNusinersen for treatment oflater-onset spinal muscular atrophy\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eDisorders of peripheral nerve\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eCritical illness neuromyopathy(updating critical illness polyneuropathy) \u0026amp; management\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eDisorders of neuromuscular transmission\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eBilevel positive airway pressure(BiPAP) for myasthenic crisis\u003c\/p\u003e\n\u003cp\u003eTensilon\u003csup\u003e®\u003c\/sup\u003ereplaced by Enlon\u003csup\u003e®\u003c\/sup\u003e (both edrophonium) for myasthenia testing\u003c\/p\u003e\n\u003cp\u003eEculizumab for treatment ofmyasthenia gravis\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 10. SensoryDisorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNew Table:\u003c\/i\u003e Pharmacologic Treatment of Pain\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eApproach to diagnosis\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eNeuropathic itch: causes \u0026amp;treatment\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePolyneuropathies\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eGuillain-Barrésyndrome associated with bone and digestive organ surgery\u003c\/p\u003e\n\u003cp\u003eAutoantibodies in chronic inflammatory demyelinatingpolyradiculoneuropathy\u003c\/p\u003e\n\u003cp\u003ePolyneuropathy with monoclonal gammopathy of uncertain significance \u003c\/p\u003e\n\u003cp\u003eFluoroquinolone-induced polyneuropathy\u003c\/p\u003e\n\u003cp\u003ePatisiran treatment of hereditarytransthyretin-mediated amyloidosis\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 11. MovementDisorders\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eParkinsonism\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eLRRK2 activation in idiopathic Parkinson disease\u003c\/p\u003e\n\u003cp\u003ePostural tremor subtypes in Parkinson disease\u003c\/p\u003e\n\u003cp\u003eLight therapy treatment of Parkinsondisease\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 12. Seizures\u0026amp; Syncope\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSeizures\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eUpdate on sustained release drugs\u003c\/p\u003e\n\u003cp\u003eSafety of anticonvulsant drugs inpregnancy and breast-feeding\u003c\/p\u003e\n\u003cp\u003eNewly approved anticonvulsantdrugs: clobazam, eslicarbazepine, perampanel, \u003c\/p\u003e\n\u003cp\u003eCannabidiol for treatment of Lennox-Gastaut\u0026amp; Dravet syndromes\u003c\/p\u003e\n\u003cp\u003eHypothermia not associated with betteroutcome in status epilepticus\u003c\/p\u003e\n\u003cp\u003eNo increased risk of seizures withattention-deficit disorder medications\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSyncope\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eRelative efficacy of nonpharmacologicinterventions for orthostatic hypotension \u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eChapter 13. Stroke\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eApproach to diagnosis\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eUpdated epidemiology ofcerebrovascular disease\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFocal cerebral ischemia—approach to diagnosis\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eTemporal trends in ischemic stroke subtypes\u003c\/p\u003e\n\u003cp\u003eFive-year risk of stroke after TIAor minor ischemic stroke (2018 study)\u003c\/p\u003e\n\u003cp\u003eFactors associated with emergencyroom misdiagnosis of stroke\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFocal cerebral ischemia—pathophysiology\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eSkull bone marrow in post-strokeinflammatory response\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFocal cerebral ischemia—etiology\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eNew perspectives on cerebral smallvessel disease\u003c\/p\u003e\n\u003cp\u003ePreeclampsia, posterior reversible encephalopathy syndrome, and stroke\u003c\/p\u003e\n\u003cp\u003eLate-life systolic and diastolicblood pressure and risk of stroke\u003c\/p\u003e\n\u003cp\u003eIntra-ictal blood pressure and poststroke cognitive impairment\u003c\/p\u003e\n\u003cp\u003eBlood lipid profiles in relationto stroke subtypes\u003c\/p\u003e\n\u003cp\u003ePsychological stress as a risk factor for stroke\u003c\/p\u003e\n\u003cp\u003eSepsis as a risk factor for stroke\u003c\/p\u003e\n\u003cp\u003eUpdate on genetics, epidemiology\u0026amp; management of cerebrovascular fibromuscular dysplasia\u003c\/p\u003e\n\u003cp\u003eUpdate on ischemic stroke incancer patients and its treatment\u003c\/p\u003e\n\u003cp\u003eStroke risk in occult and manifest cancers\u003c\/p\u003e\n\u003cp\u003eBiopsy vs. imaging findings in primaryCNS vasculitis\u003c\/p\u003e\n\u003cp\u003eUpdate on patent foramen ovaleclosure for cryptogenic stroke\u003c\/p\u003e\n\u003cp\u003eEffects of sex and aura on strokerisk in migraine\u003c\/p\u003e\n\u003cp\u003eRole of paradoxical embolism instroke in migraineurs\u003c\/p\u003e\n\u003cp\u003ePresentations and treatment updatein cerebral venous and sinus thrombosis\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFocal cerebral ischemia—prevention \u0026amp; treatment\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eLDL cholesterol target levels forsecondary stroke prevention\u003c\/p\u003e\n\u003cp\u003eStroke prevention in the veryelderly\u003c\/p\u003e\n\u003cp\u003eHypercoagulability workup for nonatheroscleroticischemic stroke\u003c\/p\u003e\n\u003cp\u003eAspirin for primary stroke preventionin diabetes mellitus\u003c\/p\u003e\n\u003cp\u003eDiagnosis \u0026amp; management of theantiphospholipid syndrome in stroke prevention p\u0026gt;\u003c\/p\u003e\n\u003cp\u003eEmbolic stroke after leftventricular endocardial ablation\u003c\/p\u003e\n\u003cp\u003eAmerican Heart Association 2018 guidelines for management of acuteischemic stroke\u003c\/p\u003e\n\u003cp\u003eAspirin ± clopidogrel for acute ischemic strokeand TIA\u003c\/p\u003e\n\u003cp\u003eBetrixaban vs. enoxaparin forstroke prophylaxis in hospitalized patients\u003c\/p\u003e\n\u003cp\u003eEzetimibe for stroke prevention inacute coronary syndrome\u003c\/p\u003e\n\u003cp\u003eRivaroxaban ±aspirin for secondary stroke prevention\u003c\/p\u003e\n\u003cp\u003eRivaroxaban vs.aspirin for secondary prevention after cryptogenic stroke\u003c\/p\u003e\n\u003cp\u003eAndexanet alfa for reversing bleeding from factor Xa inhibitor treatment\u003c\/p\u003e\n\u003cp\u003eTiming for initiating statin therapy after acute ischemic stroke\u003c\/p\u003e\n\u003cp\u003eWarfarin vs. vitamin K antagonists for embolic stroke prevention inatrial fibrillation\u003c\/p\u003e\n\u003cp\u003eReappraisal of endarterectomy forasymptomatic carotid stenosis\u003c\/p\u003e\n\u003cp\u003eLeukoaraiosis \u0026amp; risk of hemorrhage after thrombolysis\u003c\/p\u003e\n\u003cp\u003eTenecteplase versus alteplase thrombolysis before thrombectomy forischemic stroke\u003c\/p\u003e\n\u003cp\u003eSafety of thrombolysis in patients on non–vitamin K antagonist oralanticoagulants\u003c\/p\u003e\n\u003cp\u003eTime to endovascular treatment and outcome in acute ischemic stroke\u003c\/p\u003e\n\u003cp\u003eEndovascular thrombectomy 6-24hours after stroke onset\u003c\/p\u003e\n\u003cp\u003eMRI-guided thrombolysis for stroke withunknown time of onset\u003c\/p\u003e\n\u003cp\u003eEndovascular therapy for distalintracranial occlusions \u003c\/p\u003e\n\u003cp\u003eEffect of intravenous thrombolysisprior to mechanical thrombectomy on stroke outcome\u003c\/p\u003e\n\u003cp\u003eEffect of interhospital transferon stroke outcome after thrombectomy\u003c\/p\u003e\n\u003cp\u003eEmboTrap thrombectomy for acuteischemic stroke from large-vessel occlusion\u003c\/p\u003e\n\u003cp\u003eConscious sedation vs. localanesthesia for endovascular treatment of stroke \u003c\/p\u003e\n\u003cp\u003eCervical nerve transfer for limbparalysis after stroke\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFocal cerebral ischemia—complications \u0026amp; rehabilitation\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eMechanisms of cardiac complications after stroke\u003c\/p\u003e\n\u003cp\u003eHyperglycemia \u0026amp; post-strokeinfection\u003c\/p\u003e\n\u003cp\u003eMicrobiological etiologies of pneumonia complicating stroke\u003c\/p\u003e\n\u003cp\u003ePost-stroke fatigue and itstreatment\u003c\/p\u003e\n\u003cp\u003ePost-stroke anxiety subtypes\u003c\/p\u003e\n\u003cp\u003eLong-term risk of post-strokeseizures\u003c\/p\u003e\n\u003cp\u003eMechanisms of motor compensationafter stroke\u003c\/p\u003e\n\u003cp\u003eRobotic exosuits for strokerehabilitation\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eIntracerebral hemorrhage\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eEtiology of deep vs. superficial cerebellar hemorrhage\u003c\/p\u003e\n\u003cp\u003eUpdate on etiology \u0026amp; outcome of perimesencephalic hemorrhage\u003c\/p\u003e\n\u003cp\u003eRisk of intracerebral hemorrhage from warfarin vs. direct oralanticoagulants\u003c\/p\u003e\n\u003cp\u003eEffects of statins on incidence of intracerebral and subarachnoidhemorrhage\u003c\/p\u003e\n\u003cp\u003eBlood pressure target to prevent brain ischemia after intracerebralhemorrhage\u003c\/p\u003e\n\u003cp\u003eGenetics of intracranial aneurysms\u003c\/p\u003e\n\u003cp\u003eMedical vs. interventional therapy for unruptured brain AVMs: results ofrandomized trial\u003c\/p\u003e\n\u003cp\u003eSpetzler–Martin grading scale \u0026amp; treatment of brain AVMs\u003c\/p\u003e\n\u003cp\u003eUpdate on genetics and bleedingrisk of cranial cavernous malformations\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eGlobal cerebral ischemia\u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003eEarly hyperoxia and neurologicalfunction after cardiac arrest\u003c\/p\u003e\n\u003cp\u003eEpinephrine \u0026amp; neurological outcomeafter cardiac arrest\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"McGraw-Hill Education","offers":[{"title":"Default Title","offer_id":48738479538519,"sku":"9781260458350","price":73.14,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781260458350.jpg?v=1723812080","url":"https:\/\/bookcurl.com\/products\/lange-clinical-neurology-11th-edition-9781260458350","provider":"Book Curl","version":"1.0","type":"link"}